Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses.
Casper W F van EijckHassana El HaddaouiSongul KucukcelebiDisha VadgamaAmine FellahDana A M MustafaJoachim G J V AertsCasper H J van EijckMarcella WillemsenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunological tolerance by enhancing anti-tumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.